Heron Therapeuti Cash Flow Conversion Efficiency
Heron Therapeuti cash flow conversion efficiency. Based on the latest financial reports, Heron Therapeuti (HRTX) has a cash flow conversion efficiency ratio of -0.169x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.54 Million) by net assets ($9.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Heron Therapeuti (1989–2025)
Cash flow conversion efficiency of Heron Therapeuti from 1989 to 2025. This chart illustrates how Heron Therapeuti's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Heron Therapeuti for real-time trading data and today's change.
Heron Therapeuti Cash Flow Conversion Ratio Explained
Heron Therapeuti cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Heron Therapeuti Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heron Therapeuti ranked by their cash flow conversion efficiency. Also see market cap of Heron Therapeuti for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NPC Co. Ltd
KO:004250
|
0.040x |
|
Here Group Limited
NASDAQ:HERE
|
0.227x |
|
Versatile Creative Bhd
KLSE:4995
|
0.046x |
|
Interlink Electronics Inc
NASDAQ:LINK
|
0.068x |
|
Guizhou Zhongyida Co Ltd
SHG:900906
|
0.195x |
|
Choong Ang Vaccine Laboratory Co. Ltd
KQ:072020
|
0.053x |
|
Yunsa Yunlu Sanayi ve Ticaret AS
IS:YUNSA
|
0.030x |
|
SkyAI, Inc.
NASDAQ:SKYA
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Heron Therapeuti (1989–2025)
The table below shows the annual cash flow conversion efficiency of Heron Therapeuti from 1989 to 2025. Review free cash flow generation of Heron Therapeuti to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $14.33 Million | $-27.59 Million | -1.925x | -387.53% |
| 2024-12-31 | $-33.65 Million | $-22.53 Million | 0.669x | -61.31% |
| 2023-12-31 | $-33.97 Million | $-58.79 Million | 1.730x | +115.99% |
| 2022-12-31 | $13.57 Million | $-146.91 Million | -10.825x | -312.91% |
| 2021-12-31 | $77.57 Million | $-203.35 Million | -2.622x | -235.45% |
| 2020-12-31 | $236.49 Million | $-184.82 Million | -0.782x | -153.33% |
| 2019-12-31 | $403.83 Million | $-124.58 Million | -0.308x | +40.46% |
| 2018-12-31 | $370.16 Million | $-191.81 Million | -0.518x | +60.10% |
| 2017-12-31 | $131.14 Million | $-170.30 Million | -1.299x | -120.58% |
| 2016-12-31 | $-21.25 Million | $-134.10 Million | 6.310x | +1049.10% |
| 2015-12-31 | $118.11 Million | $-78.53 Million | -0.665x | +30.45% |
| 2014-12-31 | $63.06 Million | $-60.28 Million | -0.956x | -61.68% |
| 2013-12-31 | $68.94 Million | $-40.76 Million | -0.591x | -80.12% |
| 2012-12-31 | $51.82 Million | $-17.01 Million | -0.328x | +33.03% |
| 2011-12-31 | $15.75 Million | $-7.72 Million | -0.490x | +88.24% |
| 2010-12-31 | $1.32 Million | $-5.48 Million | -4.166x | -157.43% |
| 2009-12-31 | $6.80 Million | $-11.00 Million | -1.618x | +49.34% |
| 2008-12-31 | $7.60 Million | $-24.27 Million | -3.195x | -444.92% |
| 2007-12-31 | $29.47 Million | $-17.28 Million | -0.586x | -177.01% |
| 2006-12-31 | $12.06 Million | $9.18 Million | 0.761x | +162.74% |
| 2005-12-31 | $6.20 Million | $-7.53 Million | -1.213x | -121.81% |
| 2004-12-31 | $14.15 Million | $-7.74 Million | -0.547x | +5.57% |
| 2003-12-31 | $11.26 Million | $-6.53 Million | -0.579x | -74.54% |
| 2002-12-31 | $15.46 Million | $-5.13 Million | -0.332x | +1.97% |
| 2001-12-31 | $19.17 Million | $-6.49 Million | -0.339x | -129.91% |
| 2000-12-31 | $21.16 Million | $-3.12 Million | -0.147x | -194.53% |
| 1999-12-31 | $12.00 Million | $-600.00K | -0.050x | +51.67% |
| 1998-12-31 | $14.50 Million | $-1.50 Million | -0.103x | -427.59% |
| 1997-12-31 | $10.20 Million | $-200.00K | -0.020x | +98.39% |
| 1996-12-31 | $5.00 Million | $-6.10 Million | -1.220x | +25.36% |
| 1995-12-31 | $5.20 Million | $-8.50 Million | -1.635x | -124.28% |
| 1994-12-31 | $11.80 Million | $-8.60 Million | -0.729x | +34.59% |
| 1993-12-31 | $10.50 Million | $-11.70 Million | -1.114x | -477.14% |
| 1992-12-31 | $20.20 Million | $-3.90 Million | -0.193x | +83.74% |
| 1991-12-31 | $3.20 Million | $-3.80 Million | -1.188x | -120.04% |
| 1990-12-31 | $6.30 Million | $-3.40 Million | -0.540x | -34.92% |
| 1989-12-31 | $9.50 Million | $-3.80 Million | -0.400x | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more